---
---

# 21 U.S.C., USLM ref /us/usc/t21/s356e

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s356d.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s356f.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs356e)

## § 356e. Drug shortage list

    (a) __Establishment__ 

        The Secretary shall maintain an up-to-date list of drugs that are determined by the Secretary to be in shortage in the United States.

    (b) __Contents__ 

    For each drug on such list, the Secretary shall include the following information:

        (1) The name of the drug in shortage, including the National Drug Code number for such drug.

        (2) The name of each manufacturer of such drug.

        (3)

         The reason for the shortage, as determined by the Secretary, selecting from the following categories:

            (A) Requirements related to complying with good manufacturing practices.

            (B) Regulatory delay.

            (C) Shortage of an active ingredient.

            (D) Shortage of an inactive ingredient component.

            (E) Discontinuation of the manufacture of the drug.

            (F) Delay in shipping of the drug.

            (G) Demand increase for the drug.

        (4) The estimated duration of the shortage as determined by the Secretary.

    (c) __Public availability__ 

        (1) __In general__ 

            Subject to paragraphs (2) and (3), the Secretary shall make the information in such list publicly available.

        (2) __Trade secrets and confidential information__ 

            Nothing in this section alters or amends [section 1905 of title 18][/us/usc/t18/s1905] or [section 552(b)(4) of title 5][/us/usc/t5/s552/b/4].

        (3) __Public health exception__ 

            The Secretary may choose not to make information collected under this section publicly available under paragraph (1) or [section 356c(c) of this title][/us/usc/t21/s356c/c] if the Secretary determines that disclosure of such information would adversely affect the public health (such as by increasing the possibility of hoarding or other disruption of the availability of drug products to patients).

([June 25, 1938, ch. 675, § 506E][/us/act/1938-06-25/ch675/s506E], as added [Pub. L. 112–144, title X, § 1004][/us/pl/112/144/s1004], July 9, 2012, [126 Stat. 1104][/us/stat/126/1104].)

----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s356d.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s356f.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs356e)

----------
----------

[/us/usc/t18/s1905]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft18%2Fs1905
[/us/usc/t5/s552/b/4]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft5%2Fs552%2Fb%2F4
[/us/usc/t21/s356c/c]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs356c%2Fc
[/us/act/1938-06-25/ch675/s506E]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1938-06-25%2Fch675%2Fs506E
[/us/pl/112/144/s1004]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F112%2F144%2Fs1004
[/us/stat/126/1104]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F126%2F1104


